Combination Ramucirumab and Docetaxel for Urothelial Carcinoma
Daniel P. Petrylak, MD, a professor of Medicine and Urology and co-director of the Signal Transduction Research Program at Yale School of Medicine, discussed results from the phase III RANGE trial for the combination of ramucirumab (Cyramza) and docetaxel in patients with urothelial carcinoma.
Daniel P. Petrylak, MD, a professor of Medicine and Urology and co-director of the Signal Transduction Research Program at Yale School of Medicine, discussed results from the phase III RANGE trial for the combination of ramucirumab (Cyramza) and docetaxel in patients with urothelial carcinoma.
These findings demonstrated a 25% reduction in the progression-free survival (PFS) rate in the group of patients receiving ramucirumab plus docetaxel, Petrylak says. The toxicities did not significantly increase with the addition of ramucirumab to the standard treatment of docetaxel.
